Indivior Investor Relations Material

Indivior PLC is a global specialty pharmaceutical company. The Company operates through two segments: Indivior and Biotie. Indivior is focused on the development, manufacture and commercialization of products for the treatment of opioid dependence; the Company's lead product candidate is sublingual film-based buprenorphine/naloxone (SUB) that utilizes a proprietary and patented BioErodible MucoAdhesive (BEMA) technology to provide a therapeutic alternative to tablets and oral films currently used in opioid dependence treatment. Biotie is focused on developing therapeutics for diseases linked to protein aggregation and polyQ disorders including Parkinson's disease, Huntington's disease and dementia with Lewy bodies.